Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Current Deferred Revenue (2016 - 2017)

Lisata Therapeutics' Current Deferred Revenue history spans 8 years, with the latest figure at $5.4 million for Q1 2017.

  • For Q1 2017, Current Deferred Revenue fell 4.86% year-over-year to $5.4 million; the TTM value through Mar 2017 reached $5.4 million, down 4.86%, while the annual FY2016 figure was $5.1 million, 4.62% down from the prior year.
  • Current Deferred Revenue reached $5.4 million in Q1 2017 per LSTA's latest filing, up from $5.1 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $7.2 million in Q2 2016 to a low of $362041.0 in Q2 2013.
  • Average Current Deferred Revenue over 5 years is $4.0 million, with a median of $4.6 million recorded in 2015.
  • Peak YoY movement for Current Deferred Revenue: plummeted 77.81% in 2013, then surged 681.83% in 2014.
  • A 5-year view of Current Deferred Revenue shows it stood at $1.8 million in 2013, then soared by 138.58% to $4.3 million in 2014, then grew by 23.33% to $5.3 million in 2015, then decreased by 4.62% to $5.1 million in 2016, then grew by 5.23% to $5.4 million in 2017.
  • Per Business Quant, the three most recent readings for LSTA's Current Deferred Revenue are $5.4 million (Q1 2017), $5.1 million (Q4 2016), and $5.9 million (Q3 2016).